Spots Global Cancer Trial Database for Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

Official Title: Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

Study ID: NCT04962425

Conditions

Cardiac Toxicity

Antitumor Drugs

Breast Cancer

Interventions

Trastuzumab

Study Description

Brief Summary: According to the existing clinical data in our hospital, retrospective study was conducted to screen the risk factors with predictive value for TRC(trastuzumab-related cardiotoxicity) risk, and to construct the risk prediction model for TRC.

Detailed Description: The breast cancer patients with cardiotoxicity caused by trastuzumab were selected as the case group, and the breast cancer patients without cardiotoxicity were selected as the control group. The clinical baseline data, echocardiographic parameters and serum markers of the case group and the control group were compared to find out the risk factors that may have predictive value for the risk of TRC. The target factors were analyzed by univariate analysis and multivariate Logistic regression analysis, and the TRC risk prediction model was established.